Bioactive albumin-based carriers for tumour chemotherapy

Current Cancer Drug Targets

Volumn 14, Issue 8, 2014, Pages 752-763

  Shahzad, Yasser ^a   Khan, Ikram Ullah ^b,c   Hussain, Talib ^d   Alamgeer, ^e   Serra, Christophe A ^b   Rizvi, Syed A A ^f   Gerber, Minja ^a   du Plessis, Jeanetta ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

^d UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^e UNIVERSITY OF SARGODHA   (Pakistan)

^f NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Albumin; Cancer; Chemotherapy; Drug delivery; Microspheres; Nanoparticles

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 6 MERCAPTOPURINE DERIVATIVE; ALBUMIN; ALBUMIN CONJUGATE; ALBUMIN MICROSPHERE; ANTISENSE OLIGONUCLEOTIDE; CETUXIMAB; CISPLATIN; CURCUMIN; DOXORUBICIN; DRUG CARRIER; GEMCITABINE; METHOTREXATE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; SUNITINIB; TRANSFERRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ALBUMINOID; ANTINEOPLASTIC AGENT; POLYMER;

APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; HUMAN; INTERNALIZATION; MELANOMA; MEMBRANE PERMEABILITY; MICRONEEDLE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PROTEIN STRUCTURE; TUMOR VOLUME; ANIMAL; NEOPLASMS; PROCEDURES;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; POLYMERS;

EID: 84919705464     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666141028100640     Document Type: Article

References (94)

1. Patil, G.V. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev. Res., 2003, 58(3), 219-247.
2. Yewale, C.; Baradia, D.; Vhora, I.; Misra, A. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin. Drug Deliv., 2013, 10(10), 1429-1448.
3. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control. Release, 2008, 132(3), 171-183.
4. Matejtschuk, P.; Dash, C.H.; Gascoigne, E.W. Production of human albumin solution: A continually developing colloid. Br. J. Anaesth., 2000, 85(6), 887-895.
5. Ishizaka, T.; Endo, K.; Koishi, M. Preparation of egg albumin microcapsules and microspheres. J. Pharm. Sci., 1981, 70(4), 358-363.
6. Li, F.Q.; Hu, J.H.; Lu, B.; Yao, H.; Zhang, W.G. Ciprofloxacinloaded bovine serum albumin microspheres: Preparation and drugrelease in vitro. J. Microencapsul., 2001, 18(6), 825-829.
7. Kratz, F.; Elsadek, B. Clinical impact of serum proteins on drug delivery. J. Control. Rel., 2012, 161 (2), 429-445.
8. Taguchi, K.; Giam Chuang, V.T.; Maruyama, T.; Otagiri, M. Pharmaceutical aspects of the recombinant human serum albumin dimer: Structural characteristics, biological properties, and medical applications. J. Pharm. Sci., 2012, 101(9), 3033-3046.
9. Evans, T.W. Review article: Albumin as a drug - Biological effects of albumin unrelated to oncotic pressure. Aliment. Pharmacol. Ther., 2002, 16(5), 6-11.
10. Rand, M.; Murray, R. In Harper's biochemistry, 25th ed. Murray, R.; Granner, D.; Mayes, P.; Rodwell, V., Eds.; Appleton and Lange, 2000, pp 707-732.
11. Sugio, S.; Kashima, A.; Mochizuki, S.; Noda, M.; Kobayashi, K. Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng., 1999, 12(6), 439-446.
12. Mendez, C.M.; McClain, C.J.; Marsano, L.S., Albumin therapy in clinical practice. Nutr. Clin. Pract., 2005, 20(3), 314-320.
13. Tuan Giam Chuang, V.; Kragh-Hansen, U.; Otagiri, M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res., 2002, 19(5), 569-577.
14. Bosse, D.; Praus, M.; Kiessling, P.; Nyman, L.; Andresen, C.; Waters, J.; Schindel, F. Phase I comparability of recombinant human albumin and human serum albumin. J. Clinic. Pharmacol., 2005, 45(1), 57-67.
15. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet., 2006, 7(1), 21-33.
16. Madani, S.Y.; Naderi, N.; Dissanayake, O.; Tan, A.; Seifalian, A.M. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int. J. Nanomed., 2011, 6, 2963-2979.
17. Siegel, R.; Naishadham, D.; Jemal, A. Cancer Statistics, 2013. CACancer J. Clin., 2013, 63(1), 11-30.
18. Li, C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev., 2002, 54(5), 695-713.
19. DeVita Jr, V.T.; Chu, E. A history of cancer chemotherapy. Cancer Res., 2008, 68(21), 8643-8653.
20. Priestman, T.J. Cancer chemotherapy: an introduction. Springer, 1989.
21. Luo, Y.; Prestwich, G.D. Cancer-targeted polymeric drugs. Curr. Cancer Drug Targets, 2002, 2(3), 209-226.
22. Kwon, G.S. Polymeric micelles for delivery of poorly watersoluble compounds. Crit. Rev. Ther. Drug Carr. Syst., 2003, 20(5), 357-403.
23. Remesh, A. Drug resistance in cancer chemotherapy-an overview. Int. J. Cur. Res. Rev., 2013, 5(08).
24. Garnett, M.C. Targeted drug conjugates: Principles and progress. Adv. Drug Deliv. Rev., 2001, 53(2), 171-216.
25. Kawasaki, E.S.; Player, A. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomed-Nanotechnol., 2005, 1(2), 101-109.
26. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release, 2000, 65(1-2), 271-284.
27. Noguchi, Y.; Wu, J.; Duncan, R.; Strohalm, J.; Ulbrich, K.; Akaike, T.; Maeda, H. Early phase tumor accumulation of Macromolecules: A great difference in clearance rate between tumor and normal tissues. Japanese J. Cancer Res., 1998, 89(3), 307-314.
28. Kratz, F. A clinical update of using albumin as a drug vehicle - A commentary. J. Control. Release, 2014.
29. Dandagi, P.M.; Mastiholimath, V.S.; Patil, M.B.; Gupta, M.K. Biodegradable microparticulate system of captopril. Int. J. Pharm., 2006, 307(1), 83-88.
30. Edwards-Lévy, F. In Serum Albumin: Structure, Functions and Health Impact, 2012, pp 69-100.
31. Shim, T.S.; Kim, S.H.; Yang, S.M. Elaborate design strategies toward novel microcarriers for controlled encapsulation and release. Part. Part. Syst. Charact., 2013, 30(1), 9-45.
32. Lee, H.Y.; Mohammed, K.A.; Peruvemba, S.; Goldberg, E.P.; Nasreen, N. Targeted lung cancer therapy using ephrinA1-loaded albumin microspheres. J. Pharm. Pharmacol., 2011, 63(11), 1401-1410.
33. Okada, H.; Toguchi, H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carr. Syst., 1995, 12 (1), 1-99.
34. Kawaguchi, H. Functional polymer microspheres. Prog. Polym. Sci., 2000, 25(8), 1171-1210.
35. Arshady, R. Preparation of polymer nano- and microspheres by vinyl polymerization techniques. J. Microencapsul., 1988, 5(2), 101-114.
36. Chuo, W.H.; Tsai, T.R.; Hsu, S.H.; Cham, T.M. Preparation and invitro evaluation of nifedipine loaded albumin microspheres crosslinked by different glutaraldehyde concentrations. Int. J. Pharm., 1996, 144(2), 241-245.
37. Ghassabian, S.; Ehtezazi, T.; Forutan, S.M.; Mortazavi, S.A. Dexamethasone-loaded magnetic albumin microspheres: Preparation and in vitro release. Int. J. Pharm., 1996, 130(1), 49-55.
38. Park, H.Y.; Song, I.H.; Kim, J.H.; Kim, W.S. Preparation of thermally denatured albumin gel and its pH-sensitive swelling. Int. J. Pharm., 1998, 175(2), 231-236.
39. Radović, M.; Vranješ-Urić, S.; Nikolić, N.; Janković, D.; Goya, G.F.; Torres, T.E.; Calatayud, M.P.; Bruvera, I.J.; Ibarra, M.R.; Spasojević, V.; Jančar, B.; Antić, B., Development and evaluation of 90Y-labeled albumin microspheres loaded with magnetite nanoparticles for possible applications in cancer therapy. J. Mater. Chem., 2012, 22(45), 24017-24025.
40. Kramer, P.A. Albumin microspheres as vehicles for achieving specificity in drug delivery. J. Pharm. Sci., 1974, 63(10), 1646-1647.
41. Kramer, P.A.; Burnstein, T. Phagocytosis of microspheres containing an anticancer agent by tumor cells in vitro. Life Sci., 1976, 19(4), 515-519.
42. Widder, K.J.; Morris, R.M.; Poore, G.A.; Howard, D.P.; Senyei, A.E. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: Total remission in Yoshida sarcoma-bearing rats. Eur. J. Cancer, 1983, 19(1), 135-139.
43. Fujimoto, S.; Endoh, F.; Kitsukawa, Y.; Okui, K.; Morimoto, Y.; Sugibayashi, K.; Miyakawa, A.; Suzuki, H. Continued in vitro and in vivo release of an antitumor drug from albumin microspheres. Experientia, 1983, 39(8), 913-916.
44. Goldberg, J.A.; Willmott, N.S.; Anderson, J.H.; McCurrach, G.; Bessent, R.G.; McKillop, J.H.; McArdle, C.S. The biodegradation of albumin microspheres used for regional chemotherapy in patients with colorectal liver metastases. Nuclear Med. Commun., 1991, 12(1), 57-63.
45. Wang, R.; Zhong, W.; Guan, S., Daunomycin-human albumin microspheres (Dau-HA-MS). Preparation, characterization and use in experimental cancer therapy. Chinese J. Oncol., 1994, 16(2), 98-101.
46. Shah, A.U.; D'Souza, M.J. Sustained-release interleukin-12 microspheres in the treatment of cancer. Drug Dev. Ind. Pharm., 1999, 25(9), 995-1004.
47. Jones, A.K.; Bejugam, N.K.; Nettey, H.; Addo, R.; D'Souza, M.J., Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas. J. Drug Target, 2011, 19(6), 427-433.
48. Saranga-Perry, V.; Ambe, C.; Zager, J.S.; Kudchadkar, R.R. Recent developments in the medical and surgical treatment of melanoma. CA-Cancer J. Clin., 2014, 64(3), 171-185.
49. Bhowmik, T.; D'Souza, B.; Shashidharamurthy, R.; Oettinger, C.; Selvaraj, P.; D'Souza, M.J. A novel microparticulate vaccine for melanoma cancer using transdermal delivery. J. Microencapsul., 2011, 28(4), 294-300.
50. Bhojani, M.S.; Van Dort, M.; Rehemtulla, A.; Ross, B.D. Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol. Pharm., 2010, 7(6), 1921-1929.
51. Kolluru, L.P.; Rizvi, S.A.A.; D’Souza, M.; D’Souza, M.J. Formulation development of albumin based theragnostic nanoparticles as a potential delivery system for tumor targeting. J. Drug Target., 2013, 21(1), 77-86.
52. Xiong, R.; Soenen, S.J.; Braeckmans, K.; Skirtach, A.G. Towards theranostic multicompartment microcapsules: in-situ diagnostics and laser-induced treatment. Theranostics, 2013, 3(3), 141.
53. Win, K.Y.; Ye, E.; Teng, C.P.; Jiang, S.; Han, M.Y. Engineering polymeric microparticles as theranostic carriers for selective delivery and cancer therapy. Adv. Healthcare Mat., 2013, 2(12), 1571-1575.
54. Blagosklonny, M.V.; Fojo, T. Molecular effects of paclitaxel: Myths and reality (a critical review). Int. J. Cancer, 1999, 83(2), 151-156.
55. Dosio, F.; Arpicco, S.; Stella, B.; Brusa, P.; Cattel, L. Folatemediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int. J. Pharm., 2009, 382(1-2), 117-123.
56. Grinberg, O.; Hayun, M.; Sredni, B.; Gedanken, A. Characterization and activity of sonochemically-prepared BSA microspheres containing Taxol - An anticancer drug. Ultrason. Sonochem., 2007, 14(5), 661-666.
57. Hebert, C.; Norris, K.; Sauk, J.J. Targeting of human squamous carcinomas by SPA470-doxorubicin immunoconjugates. J. Drug Target., 2003, 11(2), 101-107.
58. Hanes, J.; Sills, A.; Zhao, Z.; Suh, K.W.; Tyler, B.; DiMeco, F.; Brat, D.J.; Choti, M.A.; Leong, K.W.; Pardoll, E.M.; Brem, H. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm. Res., 2001, 18(7), 899-906.
59. Muvaffak, A.; Hasirci, N. The use of antibodies in diagnosis and therapy of cancer. Adv. Exp. Med. Bio., 2003, 534, 309-325.
60. Grinberg, O.; Gedanken, A.; Mukhopadhyay, D.; Patra, C.R. Antibody modified bovine serum albumin microspheres for targeted delivery of anticancer agent Gemcitabine. Polym. Adv. Technol., 2013, 24(3), 294-299.
61. Lübbe, A.S.; Alexiou, C.; Bergemann, C. Clinical applications of magnetic drug targeting. J. Surg. Res., 2001, 95(2), 200-206.
62. Häfeli, U.O.; Sweeney, S.M.; Beresford, B.A.; Humm, J.L.; Macklis, R.M. Effective targeting of magnetic radioactive90Ymicrospheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results. Nucl. Med. Biol., 1995, 22(2), 147-155.
63. Enriquez, G.G.; Rizvi, S.A.A.; D'Souza, M.J.; Do, D.P. Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy. Int. J. Nanomed., 2013, 8, 1393-1402.
64. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nano., 2007, 2(12), 751-760.
65. Torchilin, V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev., 2006, 58(14), 1532-1555.
66. Khan, I.U.; Serra, C.A.; Anton, N.; Vandamme, T. Microfluidics: A focus on improved cancer targeted drug delivery systems. J. Control. Release, 2013, 172(3), 1065-1074.
67. Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release, 2012, 157(2), 168-182.
68. Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polym. Sci., 1975, 51(1), 135-153.
69. Dosio, F.; Brusa, P.; Crosasso, P.; Arpicco, S.; Cattel, L., Preparation, characterization and properties in vitro and in vivo of a paclitaxelalbumin conjugate. J. Control. Release, 1997, 47(3), 293-304.
70. Duncan, R.; Spreafico, F. Polymer conjugates. Clin. Pharmacokinet., 1994, 27(4), 290-306.
71. Ohkawa, K.; Hatano, T.; Yamada, K.; Joh, K.; Takada, K.; Tsukada, Y.; Matsuda, M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res., 1993, 53(18), 4238-4242.
72. Dosio, F.; Arpicco, S.; Brusa, P.; Stella, B.; Cattel, L. Poly (ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. J. Control. Release, 2001, 76(1-2), 107-117.
73. Guo, Q.; Wang, H.; Zhao, Y.; Wang, H.; Zeng, F.; Hua, H.; Xu, Q.; Huang, Y. Cell-penetrating albumin conjugates for enhanced doxorubicin delivery. Polym. Chem., 2013, 4(17), 4584-4587.
74. Taheri, A.; Dinarvand, R.; Nouri, F.S.; Khorramizadeh, M.R.; Borougeni, A.T.; Mansoori, P.; Atyabi, F. Use of biotin targeted methotrexate-human serum albumin conjugated nanoparticles to enhance methotrexate antitumor efficacy. Int. J. Nanomed., 2011, 6, 1863-1874.
75. Taheri, A.; Dinarvand, R.; Atyabi, F.; Ghahremani, M.H.; Ostad, S.N., Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur. J. Pharm. Sci., 2012, 47(2), 331-340.
76. Manoochehri, S.; Darvishi, B.; Kamalinia, G.; Amini, M.; Fallah, M.; Ostad, S.N.; Atyabi, F.; Dinarvand, R. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. DARU, 2013, 21(1), 58.
77. Gelperina, S.; Kisich, K.; Iseman, M.D.; Heifets, L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med., 2005, 172(12), 1487-1490.
78. Jong, W.H.D.; Borm, P.J. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomed., 2008, 3(2), 133-149.
79. Elsadek, B.; Kratz, F. Impact of albumin on drug delivery — New applications on the horizon. J. Control. Release, 2012, 157(1), 4-28.
80. Cucinotto, I.; Fiorillo, L.; Gualtieri, S.; Arbitrio, M.; Ciliberto, D.; Staropoli, N.; Grimaldi, A.; Luce, A.; Tassone, P.; Caraglia, M.; Tagliaferri, P. Nanoparticle albumin bound paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J. Drug Deliv., 2013, 2013, 10.
81. Cortes, J.; Saura, C., Nanoparticle albumin-bound (nab™)- paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Suppl., 2010, 8(1), 1-10.
82. Chen, D.; Tang, Q.; Xue, W.; Xiang, J.; Zhang, L.; Wang, X. The preparation and characterization of folate-conjugated human serum albumin magnetic cisplatin nanoparticles. J. Biomed. Res., 2010, 24(1), 26-32.
83. Kim, T.H.; Jiang, H.H.; Youn, Y.S.; Park, C.W.; Tak, K.K.; Lee, S.; Kim, H.; Jon, S.; Chen, X.; Lee, K.C. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int. J. Pharm., 2011, 403(1-2), 285-291.
84. Yang, L.; Cui, F.; Cun, D.; Tao, A.; Shi, K.; Lin, W. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int. J. Pharm., 2007, 340(1-2), 163-172.
85. Altintas, I.; Heukers, R.; van der Meel, R.; Lacombe, M.; Amidi, M.; van Bergen en Henegouwen, P.M.P.; Hennink, W.E.; Schiffelers, R.M.; Kok, R.J., Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J. Control. Release, 2013, 165(2), 110-118.
86. Löw, K.; Wacker, M.; Wagner, S.; Langer, K.; von Briesen, H. Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells. Nanomed.-Nanotechnol., 2011, 7(4), 454-463.
87. Wartlick, H.; Spänkuch-Schmitt, B.; Strebhardt, K.; Kreuter, J.; Langer, K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J. Control. Release, 2004, 96(3), 483-495.
88. Karmali, P.P.; Kotamraju, V.R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell, M.; Ruoslahti, E. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomed-Nanotechnol., 2009, 5(1), 73-82.
89. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 2000, 65(1-2), 271-284.
90. Wartlick, H.; Michaelis, K.; Balthasar, S.; Strebhardt, K.; Kreuter, J.; Langer, K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target., 2004, 12(7), 461-471.
91. Dreis, S.; Rothweiler, F.; Michaelis, M.; Cinatl Jr, J.; Kreuter, J.; Langer, K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm., 2007, 341(1-2), 207-214.
92. Wagner, S.; Rothweiler, F.; Anhorn, M.G.; Sauer, D.; Riemann, I.; Weiss, E.C.; Katsen-Globa, A.; Michaelis, M.; Cinatl Jr, J.; Schwartz, D.; Kreuter, J.; von Briesen, H.; Langer, K. Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials, 2010, 31(8), 2388-2398.
93. Bae, S.; Ma, K.; Kim, T.H.; Lee, E.S.; Oh, K.T.; Park, E.-S.; Lee, K.C.; Youn, Y.S., Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosisinducing ligand and transferrin for targeting multiple tumor types. Biomaterials, 2012, 33(5), 1536-1546.
94. Almasan, A.; Ashkenazi, A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine & Growth Factor Rev., 2003, 14(3-4), 337-348.